Utility of Nerve Conduction Studies for Carpal Tunnel Syndrome by Family Medicine, Primary Care, and Internal Medicine Physicians

J. Thomas Megerian, Xuan Kong, and Shai N. Gozani

Introduction: Nerve conduction studies (NCS) are increasingly being performed at the point-of-service by family medicine, primary care, and internal medicine (FM/PCP/IM) physicians. Carpal tunnel syndrome (CTS) is a common neuropathy often diagnosed with the aid of NCS.

Methods: A retrospective analysis of a point-of-service NCS data registry was conducted; 1190 patients who underwent NCS by 613 FM/PCP/IM physician practices, for evaluation of CTS were analyzed. Utility measures included demographic and electrophysiological characteristics of study population, adherence to evidence-based testing guidelines, and relevance of diagnostic outcomes.

Results: Tested patients tended to be over 40, female, and overweight or obese. The median nerve distal motor latency was 4.4 ± 1.2 ms; 92.6% of studies met the testing guideline; 30.5% of tested limbs yielded normal results; 53.1% CTS; 5.4% ulnar neuropathy; and 11.0% nonspecific upper extremity neuropathy.

Discussion: This study demonstrated that point-of-service NCS by FM/PCP/IM physicians for CTS was applied to appropriate patient subpopulations, was performed in accordance with evidence-based testing parameters, and generated relevant diagnostic outcomes. (J Am Board Fam Med 2007;20:60–4.)
As a result, CTS is an appropriate disease model for evaluating the quality and efficacy of diagnostic testing. In this study, a population-based analysis of FM/PCP/IM physician utilization of NCS for the assessment of CTS was conducted. Utilization measures included demographic characteristics of the tested population, nerve conduction values, adherence to evidence-based testing guidelines, and relevance of diagnostic outcomes.

**Methods**

All NCS performed over 10 consecutive days (January 2006) using an automated NCS instrument (NC-stat; NeuroMetrix, Inc., Waltham, MA) linked to a data registry were analyzed retrospectively. Physicians using the instrument during this period were unaware of the eventual research use of the data and were therefore blinded to the study. Instrument operation and accuracy in detecting CTS have been described. In brief, this instrument performs conventional motor and sensory NCS. It automates the technical steps of a NCS including electrode placement, skin surface temperature correction, determination of nerve stimulation intensity, and analysis of the evoked neuro-electrical responses. The system comprises “biosensors,” an electronic monitor, and a report generation system. The registry stores all electrophysiological data including raw waveforms and limited demographic information (age, height, weight, and gender). The NCS tests are typically performed by office clinical staff (ie, allied health professionals and nurses) that undergo 1 day of on-site training by the manufacturer. The instrument and the data registry have automated quality assurance software that confirms and tracks ongoing staff competence. No technical or clinical retraining was provided in advance of the data analysis period. Each study is coded with the primary clinical indication for the evaluation, from among a list that includes CTS, cubital tunnel syndrome, C8 or T1 radiculopathy, back pain, leg pain, sciatica, diabetic polyneuropathy, unspecified polyneuropathy, occupational screening, and unspecified indication. Inclusion criteria were studies 1) coded for CTS, 2) performed by a provider coded as family medicine, primary care, internal medicine, rheumatology, or endocrinology, and 3) including data for at least one median or ulnar nerve. There were no exclusion criteria. This study was performed under Institutional Review Board protocol no. 99000266 (Copernicus Group, Cary, NC).

A patient study was defined as strictly compliant with the evidence-based CTS testing guideline if it included at least one limb with both median and ulnar distal sensory measurements. A second less restrictive definition was 2 or more upper extremity distal sensory measurements. The later definition was required for comparison to a prior study based on an insurance claims database. Further data analysis was performed with individual limbs as the unit of evaluation. This analysis cohort was defined as the subset of limbs for which both median and ulnar nerve data were available. Four diagnostic outcomes, summarized in Table 1, were defined based on this electrophysiological data. Abnormalities were defined relative to the upper (latencies) or lower (amplitudes) limits of normal after adjust-

<table>
<thead>
<tr>
<th>Outcome*</th>
<th>Median Nerve†</th>
<th>Ulnar Nerve†</th>
<th>Combined MUD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DML</td>
<td>DSL</td>
<td>DML</td>
</tr>
<tr>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>CTS‡</td>
<td>Abnormal</td>
<td>Abnormal</td>
<td>Normal</td>
</tr>
<tr>
<td>Ulnar§</td>
<td>Normal</td>
<td>Normal</td>
<td>Abnormal</td>
</tr>
<tr>
<td>Nonspecific¶</td>
<td>Abnormal</td>
<td>Abnormal</td>
<td>Abnormal</td>
</tr>
</tbody>
</table>

* Normal, no neuropathy; CTS, carpal tunnel syndrome; ulnar, ulnar neuropathy; nonspecific, nonspecific upper extremity neuropathy affecting both median and ulnar nerves.
† DML, distal motor latency; DSL, distal sensory latency; MUD, median-ulnar distal sensory latency difference; normal DML or DSL, <97.5% of reference population; normal MUD, <90% of reference population; MUD threshold percentile lower than DML and DSL to match clinical practice.
‡ One of median nerve DML, median nerve DSL, or MUD must be abnormal.
§ One of ulnar nerve DML or DSL must be abnormal.
¶ One of median nerve DML or DSL must be abnormal and one of ulnar nerve DML or DSL must be abnormal.

Table 1. Definition of Electrophysiological Diagnostic Outcomes
ing electrophysiological measurements for skin surface temperature, patient height, and age. Each limb was assigned a diagnostic outcome (normal, CTS, ulnar neuropathy, or nonspecific upper extremity neuropathy) using these definitions.

**Results**

The initial data set consisted of NCS from 1190 patients performed by 613 different FM/PCP/IM physician practices. Mean patient age was 53.3 ± 13.3 years with 80.7% 40 years or older, and 27.8% 65 years or older (see Table 2 for study group demographics). Of the patients, 71.6% were female, and the mean body mass index (BMI) was 30.3 ± 6.9 kg/m² with 9.1% morbidly obese (BMI ≥40). Studies in 971 (81.6%) and 1102 (92.6%) patients adhered to the strict and less restrictive CTS testing guidelines, respectively, and were further analyzed. Among these studies, 1585 limbs had both median and ulnar nerve data and represented the analysis cohort. The median nerve distal motor latency (DML) was 4.4 ± 1.2 ms (8 of 1585 limbs did not have a median nerve DML). Among limbs in the analysis cohort, 483 (30.5%) had normal NCS, 842 (53.1%) indicated CTS, 86 (5.4%) identified an ulnar neuropathy, and 174 (11.0%) limbs were labeled a nonspecific neuropathy involving both the median and ulnar nerves.

**Discussion**

In a commercial insurance claims analysis of NCS procedures, Dillingham and colleagues showed that up to 25% of physician-supervised studies were performed by physicians who were not neurologists or PM&R physicians. There are clinical, patient satisfaction, and potentially economic reasons for expanding access to reliable NCS, particularly early in the episode of care. Given these factors, it is likely that point-of-service NCS by FM/PCP/IM physicians will continue expanding.

This study showed that NCS was used by FM/PCP/IM physicians for evaluation of CTS in patients that were typically female, >40 years of age, and overweight or obese. These demographic features are strongly associated with a higher risk of CTS. The average median nerve DML was 4.4 ms, which was 2.3 normal deviates above the mean value for asymptomatic disease free limbs. These demographic and electrophysiological characteristics suggest that for CTS, point-of-service NCS was applied to the appropriate patient subgroup.

Practitioner adherence to accepted clinical guidelines has been used as an outcome measure when evaluating technological advances and procedure performance by primary care specialists. In this study, 81.6% of NCS studies performed by FM/PCP/IM physicians, for evaluation of CTS, met the strict evidence-based testing guideline. Using a less restrictive definition adopted by Storm and colleagues, 91.6% satisfied the guideline. Both metrics are comparable to 86.4% adherence by neurologists and PM&R physicians reported in the Storm study, which was based on Medicare patients who went on to carpal tunnel release surgery. The high rate of compliance by FM/PCP/IM physicians employing point-of-service NCS confirms that their patients received standard-of-care testing.

An important measure of diagnostic value is the diversity among the diagnostic outcomes. It is intuitively clear that a test yielding the same reading in most individuals within a population is not informative because it is unlikely to result in differentiated treatment. Conversely, if a variety of diagnostic outcomes occur, then the test results partition the population into groups that may benefit from different interventions. In this study, CTS

<table>
<thead>
<tr>
<th>Table 2. Study Group Demographic Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Range (% Total)</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td>&lt;30 (5.9)</td>
</tr>
<tr>
<td>30–39 (13.4)</td>
</tr>
<tr>
<td>40–49 (21.3)</td>
</tr>
<tr>
<td>50–59 (22.8)</td>
</tr>
<tr>
<td>60–69 (15.7)</td>
</tr>
<tr>
<td>≥70 (20.8)</td>
</tr>
</tbody>
</table>

* Mean (standard deviation).
was identified in 53.1% of tested limbs; in another 30.5% the study was normal. Therefore in 83.6% of tested limbs, the specific diagnostic question of whether the patient had or did not have CTS was addressed by the point-of-service NCS. This high rate suggests that pretest patient selection led to clinically relevant studies. A potential criticism of point-of-service NCS by FM/PCP/IM physicians was that the studies would be mostly used in normal patients for which testing was not clinically informative or many studies would yield nonspecific results. These theoretical arguments were contradicted by the results of this study. In fact, the results were similar to a claims-based analysis of CTS testing by neurologists and PM&R physicians. Approximately 11% of the limbs were labeled with a nonspecific neuropathy. This classification was based entirely on abnormalities of ipsilateral median and ulnar nerve data for each limb. Data from the contralateral limb and lower extremities were not considered and would be expected to reduce the number of nonspecific neuropathies.

The aforementioned conclusions are predicated on an assumption of instrument accuracy in detecting CTS. The validity of automated distal latency measurements, in the median and ulnar nerves, has been confirmed by high correlation (coefficients typically 0.85 to 0.95) to blinded traditional electromyography laboratories. These coefficients are comparable to inter-examiner correlation between board certified electromyographers. In 3 studies meeting class I or II evidence-based criteria, the positive and negative likelihood ratios for CTS ranged from 8.6 to >10 and 4.3 to 8.6, respectively (likelihood ratios calculated from reported sensitivity, specificity, and raw agreement). These likelihood ratios represent clinically meaningful changes from pretest to post-test disease probability in terms of both ruling-in and ruling-out CTS.

This study had several limitations. First, data from a single NCS registry, associated with a specific electrodiagnostic instrument, were analyzed. This might lead to selection bias because participating physicians had greater electrodiagnostic knowledge than the general FM/PCP/IM physician population. Second, only studies coded for CTS testing were analyzed. It was possible that patients coded for CTS had the most distinct clinical presentations and therefore electrodiagnostic results might be expected to be most definitive. Examination of studies coded for ulnar neuropathies and other upper extremity neuropathies would be valuable. However, approximately 71% of all upper extremity studies during the evaluation period were coded for CTS. Third, studies identified as normal or CTS were defined as diagnostically specific although subsequent clinical outcomes were not measured. CTS is a well defined neurophysiological entity with a treatment pathway guided by confirmation of a focal median neuropathy at the wrist and determination of its severity. For example, abnormal median nerve DML measured by this electrodiagnostic instrument was predictive of post carpal tunnel release improvement in median nerve function. As a result, definitive detection of CTS or its exclusion (ie, normal diagnostic outcome) was a valid and useful clinical outcome. Fourth, this study did not evaluate FM/PCP/IM physician clinical interpretation of the NCS data. There is no “gold standard” for neurophysiological diagnosis as subjectivity and bias lead to limited inter-examiner interpretation agreement even among physicians regarded as experts. Medium and long-term clinical outcomes such as symptom resolution and patient satisfaction could be used to evaluate the quality of diagnostic interpretations; however, such studies have yet to be performed for traditional electrodiagnostic studies by neurologists and PM&R physicians.

References
6. Duncan KH, Lewis RC Jr., Foreman KA, Nordyke MD. Treatment of carpal tunnel syndrome by members of the American Society for Surgery of the


